[시장보고서]세계의 불면증 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2025-2032년)

세계의 불면증 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2025-2032년)

Insomnia Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

상품코드 : 1623936

리서치사 : Persistence Market Research

발행일 : 2025년 01월

페이지 정보 : 영문 163 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,211,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,532,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 12,265,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계 불면증 치료제 시장 규모는 2025년 31억 달러에 이르고, 2025-2032년의 예측 기간 동안 4.60%의 연평균 복합 성장률(CAGR)로 확대되어 2032년에는 42억 달러에 달할 전망입니다.

세계 불면증 치료 시장은 약리학적 치료, 일반의약품(OTC), 인지행동치료(CBT-I) 등 불면증 완화를 위한 다양한 치료 솔루션으로 구성됩니다. 이 시장은 주로 불면증 유병률 증가, 노인 인구 증가, 효과적이고 합리적인 가격의 치료에 대한 수요 증가에 의해 주도되고 있습니다. 또한, 치료 옵션의 혁신과 미진단 환자 증가는 불면증 치료 시장의 미래를 형성하고 있습니다.

불면증 치료 시장의 성장은 몇 가지 중요한 요인에 의해 주도되고 있습니다. 첫째, 미진단 상태를 포함한 불면증으로 고통받는 사람들 증가로 인해 치료에 대한 긴급한 수요가 발생하고 있습니다. 또한, 전 세계 인구의 고령화, 특히 60세 이상 인구는 수면장애를 겪기 쉬워 OTC 수면 보조제에 대한 수요가 더욱 증가하고 있습니다. 멜라토닌과 유니솜 수면젤과 같은 OTC 의약품은 부작용이 적어 시장을 독점하고 있으며, 2026년까지 시장 수익에서 가장 큰 비중을 차지할 것으로 예상됩니다. 또한, 제약회사들은 새로운 약리학적 치료법을 발견하기 위해 연구개발에 많은 투자를 하고 있으며, 이는 환자들에게 선택의 폭을 넓혀주고 있습니다.

미진단 불면증에 대한 인식이 높아지는 것은 시장 관계자들에게 큰 기회가 될 것입니다. 중국, 인도 등 신흥국에서의 환자 기반 확대는 새로운 성장의 길을 열어주고 있습니다. 인지행동치료(CBT-i) 및 기타 비약물적 치료법에 대한 관심이 높아지면서 약리학적인 해결책을 보완할 것으로 예상됩니다. 또한, 수백만 명의 사람들이 수면 보조제에 지출하고 있는 수면 건강 경제는 제약회사, 의료 서비스 제공업체 및 소매업체에게 수십억 달러 규모 시장 기회를 제공할 것입니다. 개인 맞춤형 의료와 혁신적인 약물 전달 메커니즘에 대한 관심이 높아짐에 따라 환자들의 순응도가 높아지면서 성장 잠재력이 더욱 커지고 있습니다.

이 보고서는 전 세계 불면증 치료제 시장을 조사했으며, 약품 유형별, 유통 채널별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

경쟁 대시보드
경쟁 벤치마킹
경쟁 별 수익성과 총이익 분석
기업 상세
- Merck & Co. Inc.
- Natrol, LLC
- GlaxoSmithKline Plc.
- Sanofi SA
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Mallinckrodt
- PERNIX Therapeutics
- Takeda Pharmaceutical Company Limited
- Sunovion Pharmaceuticals, Inc.

제14장 세계의 불면증 치료 시장 분석(2020년-2024년) 및 예측(2025년-2032년), 지역별

제15장 세계의 불면증 치료 분석(2020년-2024년) 및 예측(2025년-2032년), 약제 유형별

제16장 세계의 불면증 치료 시장 분석(2020년-2024년) 및 예측(2025년-2032년), 유통 채널별

제17장 세계의 불면증 치료 시장 분석(2020년-2024년) 및 예측(2025년-2032년)

제18장 조사 방법

LSH

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the global Insomnia Treatment Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

Insomnia Treatment Market Size (2025E): US$ 3.1 Billion
Projected Market Value (2032F): US$ 4.2 Billion
Global Market Growth Rate (CAGR 2025 to 2032): 4.60%

Insomnia Treatment Market - Report Scope:

The global insomnia treatment market comprises various therapeutic solutions aimed at alleviating insomnia, including pharmacological treatments, over-the-counter (OTC) medications, and cognitive behavioral therapies (CBT-I). The market is primarily driven by the rising prevalence of insomnia, a growing geriatric population, and increasing demand for effective and affordable treatments. Additionally, innovation in treatment options and an expanding undiagnosed patient pool are shaping the future of the insomnia treatment market.

Market Drivers:

The market growth of insomnia treatment is propelled by several key factors. Firstly, the increasing number of people suffering from insomnia, including those with undiagnosed conditions, creates an urgent demand for treatment. Additionally, the aging global population, especially individuals over 60, is more prone to sleep disorders, further driving demand for OTC sleep aids. OTC medications such as melatonin and Unisom sleep gel dominate the market due to their minimal side effects, with these products expected to capture the largest share of market revenue through 2026. Furthermore, pharmaceutical companies are investing heavily in research and development to discover new pharmacological treatments, expanding the variety of options available to patients.

Market Restraints:

Despite the promising growth prospects, the insomnia treatment market faces several challenges. One significant restraint is the high cost associated with research and development for new therapies. Moreover, regulatory barriers can slow down the introduction of new treatments, especially in emerging markets. Additionally, the complexity and variability of insomnia diagnoses can result in delayed or misdiagnosed cases, limiting the effectiveness of some therapeutic interventions. Furthermore, the availability of alternative treatments, such as behavioral therapies, may limit the demand for pharmacological solutions in certain markets.

Market Opportunities:

The growing recognition of undiagnosed insomnia presents a significant opportunity for market players. The expanding patient base in emerging economies, such as China and India, further opens up new avenues for growth. The rising interest in cognitive behavioral therapy (CBT-I) and other non-pharmacological treatments is expected to complement pharmacological solutions. Additionally, with millions spending on sleep aids, the burgeoning sleep-health economy represents a multi-billion-dollar market opportunity for pharmaceutical companies, health service providers, and retailers. The increasing focus on personalized medicine and innovative drug delivery mechanisms enhances patient compliance, creating further growth potential.

Key Questions Answered in the Report:

What are the primary factors driving the global growth of the insomnia treatment market?
How does the increasing geriatric population contribute to market expansion?
What are the emerging trends and future projections for the global insomnia treatment market?
How are pharmaceutical companies innovating in the insomnia treatment space?
Who are the key players in the insomnia treatment market, and what strategies are they employing to stay competitive?

Competitive Intelligence and Business Strategy:

Leading companies in the insomnia treatment market, such as Pfizer Inc., Sanofi, and Merck & Co., are focusing on clinical research, product innovation, and expanding their portfolios to maintain a competitive edge. These companies are leveraging partnerships and collaborations to speed up the development of new insomnia therapies. Furthermore, advancements in drug delivery technologies, including oral capsules and targeted formulations, are helping to improve patient compliance and overall treatment effectiveness. These strategies aim to cater to the growing demand for effective insomnia solutions, especially in the face of an expanding, diverse global patient pool.

Key Companies Profiled:

Sunovion Pharmaceuticals, Inc.
Natrol, LLC
GlaxoSmithKline Plc.
Sanofi SA
Pfizer Inc.
Boehringer Ingelheim International GmbH
Mallinckrodt
PERNIX Therapeutics
Takeda Pharmaceutical Company Limited
Merck & Co. Inc.
Others.

Insomnia Treatment Market Segmentation:

By Drug Type:

OTC Drugs
Prescription Drugs

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e commerce
Drug Stores
Others

By Region:

North America
Latin America
Europe
Asia Pacific excluding China (APEC)
China
Middle East and Africa (MEA)

1. Executive Summary

1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune

2. Market Introduction

2.1. Market Definition
2.2. Market Taxonomy
2.3. Inclusion and Exclusion

3. Market Dynamics

3.1. Macro-Economic Factors
3.2. Drivers
3.3. Restraints
3.4. Opportunity Analysis
3.5. Trends

4. Macroeconomic Assumptions

5. Global Economic Outlook

5.1. Gross Domestic Product by Region & Country, 2025 - 2032
5.2. Healthcare Sector Outlook
5.3. Healthcare Indicators

6. Key Inclusions

6.1. Epidemiology of Insomnia, By Region

7. North America Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

7.1. Introduction
7.2. Regional Market Trends
7.3. Historical Market Size (US$ Bn) Trend Analysis By Country, 2020 - 2024
- 7.3.1. U.S.
- 7.3.2. Canada
7.4. Market Size (US$ Bn) Forecast By Country, 2025 - 2032
7.5. Historical Market Size (US$ Bn) Trend Analysis By Drug Type, 2020 - 2024
- 7.5.1. OTC Drugs
  - 7.5.1.1. OTC Sleep Aids
  - 7.5.1.2. OTC Sleep Supplements
- 7.5.2. Prescription Drugs
7.6. Market Size (US$ Bn) Forecast By Drug Type, 2025 - 2032
7.7. Historical Market Size (US$ Bn) Trend Analysis By Distribution Channel, 2020 - 2024
- 7.7.1. Hospital Pharmacies
- 7.7.2. Retail Pharmacies
- 7.7.3. e commerce
- 7.7.4. Drug Stores
- 7.7.5. Others
7.8. Market Size (US$ Bn) Forecast By Distribution Channel, 2025 - 2032
7.9. Market Attractiveness Analysis
- 7.9.1. By Country
- 7.9.2. By Drug Type
- 7.9.3. By Distribution Channel

8. Latin America Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

8.1. Introduction
8.2. Regional Market Trends
8.3. Historical Market Size (US$ Bn) Trend Analysis By Country, 2020 - 2024
- 8.3.1. Argentina
- 8.3.2. Brazil
- 8.3.3. Mexico
- 8.3.4. Rest of Latin America
8.4. Market Size (US$ Bn) Forecast By Country, 2025 - 2032
8.5. Historical Market Size (US$ Bn) Trend Analysis By Drug Type, 2020 - 2024
- 8.5.1. OTC Drugs
  - 8.5.1.1. OTC Sleep Aids
  - 8.5.1.2. OTC Sleep Supplements
- 8.5.2. Prescription Drugs
8.6. Market Size (US$ Bn) Forecast By Drug Type, 2025 - 2032
8.7. Historical Market Size (US$ Bn) Trend Analysis By Distribution Channel, 2020 - 2024
- 8.7.1. Hospital Pharmacies
- 8.7.2. Retail Pharmacies
- 8.7.3. e commerce
- 8.7.4. Drug Stores
- 8.7.5. Others
8.8. Market Size (US$ Bn) Forecast By Distribution Channel, 2025 - 2032
8.9. Market Attractiveness Analysis
- 8.9.1. By Country
- 8.9.2. By Drug Type
- 8.9.3. By Distribution Channel

9. Europe Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

9.1. Introduction
9.2. Regional Market Trends
9.3. Historical Market Size (US$ Bn) Trend Analysis By Country, 2020 - 2024
- 9.3.1. Germany
- 9.3.2. U.K.
- 9.3.3. France
- 9.3.4. Italy
- 9.3.5. Spain
- 9.3.6. Russia
- 9.3.7. Poland
- 9.3.8. Rest of Europe
9.4. Market Size (US$ Bn) Forecast By Country, 2025 - 2032
9.5. Historical Market Size (US$ Bn) Trend Analysis By Drug Type, 2020 - 2024
- 9.5.1. OTC Drugs
  - 9.5.1.1. OTC Sleep Aids
  - 9.5.1.2. OTC Sleep Supplements
- 9.5.2. Prescription Drugs
9.6. Market Size (US$ Bn) Forecast By Drug Type, 2025 - 2032
9.7. Historical Market Size (US$ Bn) Trend Analysis By Distribution Channel, 2020 - 2024
- 9.7.1. Hospital Pharmacies
- 9.7.2. Retail Pharmacies
- 9.7.3. e commerce
- 9.7.4. Drug Stores
- 9.7.5. Others
9.8. Market Size (US$ Bn) Forecast By Distribution Channel, 2025 - 2032
9.9. Market Attractiveness Analysis
- 9.9.1. By Country
- 9.9.2. By Drug Type
- 9.9.3. By Distribution Channel

10. Asia Pacific Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

10.1. Introduction
10.2. Regional Market Trends
10.3. Historical Market Size (US$ Bn) Trend Analysis By Country, 2020 - 2024
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. India
- 10.3.4. Australia and New Zealand
- 10.3.5. ASEAN
- 10.3.6. Rest of Asia Pacific
10.4. Market Size (US$ Bn) Forecast By Country, 2025 - 2032
10.5. Historical Market Size (US$ Bn) Trend Analysis By Drug Type, 2020 - 2024
- 10.5.1. OTC Drugs
  - 10.5.1.1. OTC Sleep Aids
  - 10.5.1.2. OTC Sleep Supplements
- 10.5.2. Prescription Drugs
10.6. Market Size (US$ Bn) Forecast By Drug Type, 2025 - 2032
10.7. Historical Market Size (US$ Bn) Trend Analysis By Distribution Channel, 2020 - 2024
- 10.7.1. Hospital Pharmacies
- 10.7.2. Retail Pharmacies
- 10.7.3. e commerce
- 10.7.4. Drug Stores
- 10.7.5. Others
10.8. Market Size (US$ Bn) Forecast By Distribution Channel, 2025 - 2032
10.9. Market Attractiveness Analysis
- 10.9.1. By Country
- 10.9.2. By Drug Type
- 10.9.3. By Distribution Channel

11. Middle East & Africa Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

11.1. Introduction
11.2. Key Regulations
11.3. Historical Market Size (US$ Bn) Trend Analysis By Country, 2020 - 2024
- 11.3.1. GCC Countries
- 11.3.2. South Africa
- 11.3.3. Rest of MEA
11.4. Market Size (US$ Bn) Forecast By Country, 2025 - 2032
11.5. Historical Market Size (US$ Bn) Trend Analysis By Drug Type, 2020 - 2024
- 11.5.1. OTC Drugs
  - 11.5.1.1. OTC Sleep Aids
  - 11.5.1.2. OTC Sleep Supplements
- 11.5.2. Prescription Drugs
11.6. Market Size (US$ Bn) Forecast By Drug Type, 2025 - 2032
11.7. Historical Market Size (US$ Bn) Trend Analysis By Distribution Channel, 2020 - 2024
- 11.7.1. Hospital Pharmacies
- 11.7.2. Retail Pharmacies
- 11.7.3. e commerce
- 11.7.4. Drug Stores
- 11.7.5. Others
11.8. Market Size (US$ Bn) Forecast By Distribution Channel, 2025 - 2032
11.9. Market Attractiveness Analysis
- 11.9.1. By Country
- 11.9.2. By Drug Type
- 11.9.3. By Distribution Channel

12. Forecast Factors: Relevance and Impact

13. Competition Analysis

13.1. Competition Dashboard
13.2. Competition Benchmarking
13.3. Profitability and Gross Margin Analysis By Competition
13.4. Company Deep Dive
- 13.4.1. Merck & Co. Inc.
  - 13.4.1.1. Overview
  - 13.4.1.2. Product and Technology Portfolio
  - 13.4.1.3. Production Footprint
  - 13.4.1.4. Sales Footprint
  - 13.4.1.5. Channel Footprint
  - 13.4.1.6. Strategy
    - 13.4.1.6.1. Marketing Strategy
    - 13.4.1.6.2. Product Strategy
    - 13.4.1.6.3. Channel Strategy
- 13.4.2. Natrol, LLC
  - 13.4.2.1. Overview
  - 13.4.2.2. Product and Technology Portfolio
  - 13.4.2.3. Production Footprint
  - 13.4.2.4. Sales Footprint
  - 13.4.2.5. Channel Footprint
  - 13.4.2.6. Strategy
    - 13.4.2.6.1. Marketing Strategy
    - 13.4.2.6.2. Product Strategy
    - 13.4.2.6.3. Channel Strategy
- 13.4.3. GlaxoSmithKline Plc.
  - 13.4.3.1. Overview
  - 13.4.3.2. Product and Technology Portfolio
  - 13.4.3.3. Production Footprint
  - 13.4.3.4. Sales Footprint
  - 13.4.3.5. Channel Footprint
  - 13.4.3.6. Strategy
    - 13.4.3.6.1. Marketing Strategy
    - 13.4.3.6.2. Product Strategy
    - 13.4.3.6.3. Channel Strategy
- 13.4.4. Sanofi SA
  - 13.4.4.1. Overview
  - 13.4.4.2. Product and Technology Portfolio
  - 13.4.4.3. Production Footprint
  - 13.4.4.4. Sales Footprint
  - 13.4.4.5. Channel Footprint
  - 13.4.4.6. Strategy
    - 13.4.4.6.1. Marketing Strategy
    - 13.4.4.6.2. Product Strategy
    - 13.4.4.6.3. Channel Strategy
- 13.4.5. Pfizer Inc.
  - 13.4.5.1. Overview
  - 13.4.5.2. Product and Technology Portfolio
  - 13.4.5.3. Production Footprint
  - 13.4.5.4. Sales Footprint
  - 13.4.5.5. Channel Footprint
  - 13.4.5.6. Strategy
    - 13.4.5.6.1. Marketing Strategy
    - 13.4.5.6.2. Product Strategy
    - 13.4.5.6.3. Channel Strategy
- 13.4.6. Boehringer Ingelheim International GmbH
  - 13.4.6.1. Overview
  - 13.4.6.2. Product and Technology Portfolio
  - 13.4.6.3. Production Footprint
  - 13.4.6.4. Sales Footprint
  - 13.4.6.5. Channel Footprint
  - 13.4.6.6. Strategy
    - 13.4.6.6.1. Marketing Strategy
    - 13.4.6.6.2. Product Strategy
    - 13.4.6.6.3. Channel Strategy
- 13.4.7. Mallinckrodt
  - 13.4.7.1. Overview
  - 13.4.7.2. Product and Technology Portfolio
  - 13.4.7.3. Production Footprint
  - 13.4.7.4. Sales Footprint
  - 13.4.7.5. Channel Footprint
  - 13.4.7.6. Strategy
    - 13.4.7.6.1. Marketing Strategy
    - 13.4.7.6.2. Product Strategy
    - 13.4.7.6.3. Channel Strategy
- 13.4.8. PERNIX Therapeutics
  - 13.4.8.1. Overview
  - 13.4.8.2. Product and Technology Portfolio
  - 13.4.8.3. Production Footprint
  - 13.4.8.4. Sales Footprint
  - 13.4.8.5. Channel Footprint
  - 13.4.8.6. Strategy
    - 13.4.8.6.1. Marketing Strategy
    - 13.4.8.6.2. Product Strategy
    - 13.4.8.6.3. Channel Strategy
- 13.4.9. Takeda Pharmaceutical Company Limited
  - 13.4.9.1. Overview
  - 13.4.9.2. Product and Technology Portfolio
  - 13.4.9.3. Production Footprint
  - 13.4.9.4. Sales Footprint
  - 13.4.9.5. Channel Footprint
  - 13.4.9.6. Strategy
    - 13.4.9.6.1. Marketing Strategy
    - 13.4.9.6.2. Product Strategy
    - 13.4.9.6.3. Channel Strategy
- 13.4.10. Sunovion Pharmaceuticals, Inc.
  - 13.4.10.1. Overview
  - 13.4.10.2. Product and Technology Portfolio
  - 13.4.10.3. Production Footprint
  - 13.4.10.4. Sales Footprint
  - 13.4.10.5. Channel Footprint
  - 13.4.10.6. Strategy
    - 13.4.10.6.1. Marketing Strategy
    - 13.4.10.6.2. Product Strategy
    - 13.4.10.6.3. Channel Strategy

14. Global Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032, By Region

14.1. Introduction/Key Findings
14.2. Historical Market Size (US$ Bn)Trend Analysis By Region, 2020 - 2024
14.3. Market Size (US$ Bn) Forecast By Region, 2025 - 2032
- 14.3.1. North America
- 14.3.2. Latin America
- 14.3.3. Europe
- 14.3.4. Asia Pacific Excluding China
- 14.3.5. China
- 14.3.6. Middle East & Africa
14.4. Market Attractiveness Analysis By Region

15. Global Insomnia Treatment Analysis 2020 - 2024 and Forecast 2025 - 2032, By Drug Type

15.1. Introduction/Key Findings
15.2. Historical Market Size (US$ Bn) Trend Analysis By Drug Type, 2020 - 2024
- 15.2.1. OTC Drugs
  - 15.2.1.1. OTC Sleep Aids
  - 15.2.1.2. OTC Sleep Supplements
- 15.2.2. Prescription Drugs
15.3. Market Size (US$ Bn) Forecast By Drug Type, 2025 - 2032
15.4. Market Attractiveness Analysis By Drug Type

16. Global Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032, By Distribution Channel

16.1. Introduction/Key Findings
16.2. Historical Market Size (US$ Bn) Trend Analysis By Distribution Channel, 2020 - 2024
- 16.2.1. Hospital Pharmacies
- 16.2.2. Retail Pharmacies
- 16.2.3. e commerce
- 16.2.4. Drug Stores
- 16.2.5. Others
16.3. Market Size (US$ Bn) Forecast By Distribution Channel, 2025 - 2032
16.4. Market Attractiveness Analysis By Distribution Channel

17. Global Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

17.1. Market Value Share Analysis
17.2. Y-o-Y Growth Analysis
17.3. Absolute $ Opportunity

한글목차

목차

제1장 주요 요약

제2장 시장 서론

제3장 시장 역학

제4장 거시경제 전제

제5장 세계 경제 전망

제6장 주요 내용

제7장 북미의 불면증 치료 시장 분석(2020년-2024년) 및 예측(2025년-2032년)

제8장 라틴아메리카의 불면증 치료 시장 분석(2020년-2024년) 및 예측(2025년-2032년)

제9장 유럽의 불면증 치료 시장 분석(2020년-2024년) 및 예측(2025년-2032년)

제10장 아시아태평양의 불면증 치료 시장 분석(2020년-2024년) 및 예측(2025년-2032년)

제11장 중동 및 아프리카의 불면증 치료 시장 분석(2020년-2024년) 및 예측(2025년-2032년)

제12장 예측 요인 : 관련성과 영향

제13장 경쟁 분석